Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

587
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
587
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HLA-B alleles confer susceptibility to sulfasalazine-induced severe cutaneous adverse reactions.

The Journal of allergy and clinical immunology·2026
Same author

Dermatologic outcomes associated with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a large-scale target trial emulation.

Frontiers in endocrinology·2026
Same author

Efficacy and Safety of Intensity-Modulated Radiotherapy Combined With Regorafenib With or Without Immune Checkpoint Inhibitors as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Real-World Cohort Study From a Single Center.

Cancer medicine·2026
Same author

Impact of wideband phase-sensitive inversion recovery motion corrected late gadolinium imaging on 3T cardiac magnetic resonance image quality and diagnostic utility in patients with cardiac implantable electronic devices.

Heart rhythm O2·2026
Same author

Epidemiology, biomarkers, and therapeutic approach in early-stage biliary tract cancers.

Chinese clinical oncology·2026
Same author

Optimizing Workflow for OncotypeDX Result Turnaround Time at a Safety Net Hospital.

Global journal on quality and safety in healthcare·2026

Related Experiment Video

Updated: Aug 1, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.9K

Immunotherapy for recurrent hepatocellular carcinoma.

Ahan Bhatt1, Jennifer Wu2

  • 1Division of Hematology and Oncology, Perlmutter Cancer Center of NYU Langone Health, NYU School of Medicine, New York, NY 10016, United States.

World Journal of Gastroenterology
|May 1, 2023
PubMed
Summary

Immunotherapy options for recurrent hepatocellular carcinoma (HCC) are expanding. This review covers programmed cell death protein 1 (PD-1) and other agents for patients with recurrent HCC, including those previously treated.

Keywords:
CTLA-4 inhibitor.Combination drug therapyImmune checkpoint blockadeLiver neoplasmsPD-1- PD-L1 blockade

More Related Videos

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma
08:25

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Published on: April 25, 2025

246
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

518

Related Experiment Videos

Last Updated: Aug 1, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.9K
Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma
08:25

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Published on: April 25, 2025

246
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

518

Area of Science:

  • Hepatology and Oncology
  • Immunotherapy Research
  • Clinical Trial Analysis

Background:

  • Hepatocellular carcinoma (HCC) frequently presents late or recurs post-treatment, limiting curative options.
  • Recurrent HCC often lacks curative or local treatment efficacy, especially after prior systemic therapy.
  • Immunotherapy (IO) offers new hope for patients with advanced or recurrent HCC.

Purpose of the Study:

  • To review current and investigational immunotherapy options for recurrent HCC.
  • To discuss IO strategies for patients with no prior systemic therapy and those previously treated.
  • To provide an overview of programmed cell death protein 1 (PD-1) based therapies.

Main Methods:

  • Mini-review of existing literature on HCC immunotherapy.
  • Analysis of treatment guidelines and clinical trial data.
  • Exploration of PD-1 inhibitors, combination therapies, and novel agents.

Main Results:

  • Several immunotherapy options exist for recurrent HCC, including PD-1 inhibitors and combination therapies.
  • Investigational therapies combine PD-1 inhibitors with tyrosine kinase inhibitors or novel agents.
  • Treatment approaches vary based on prior systemic therapy exposure.

Conclusions:

  • Immunotherapy represents a significant advancement in managing recurrent HCC.
  • Optimizing IO strategies is crucial for improving patient outcomes in HCC.
  • Further research into novel combinations and treatment sequencing is warranted.